Samlyn Capital LLC Buys Shares of 45,914 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Samlyn Capital LLC has made a substantial new investment of $29.12 million in Regeneron Pharmaceuticals, acquiring approximately 45,914 shares during the first quarter.
• Analysts have varying outlooks for Regeneron, with Morgan Stanley maintaining an "overweight" rating and a price target increase to $761.00, while JPMorgan Chase & Co. has lowered its target from $950.00 to $800.00.
• Regeneron Pharmaceuticals reported a surge in earnings for the last quarter, with an EPS of $12.89 compared to a consensus estimate of $8.43, alongside revenues of $3.68 billion.

Samlyn Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 45,914 shares of the biopharmaceutical company's stock, valued at approximately $29,120,000.

Several other institutional investors have also bought and sold shares of REGN. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares in the last quarter. American Assets Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $427,000. Cary Street Partners Financial LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $865,000. Captrust Financial Advisors boosted its stake in Regeneron Pharmaceuticals by 8.6% in the 4th quarter. Captrust Financial Advisors now owns 9,916 shares of the biopharmaceutical company's stock valued at $7,064,000 after buying an additional 786 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Regeneron Pharmaceuticals by 5.6% in the 4th quarter. Cetera Investment Advisers now owns 9,239 shares of the biopharmaceutical company's stock valued at $6,581,000 after buying an additional 494 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Citigroup reissued a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Finally, Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $1.91 on Tuesday, reaching $556.53. The company's stock had a trading volume of 872,717 shares, compared to its average volume of 953,935. The company has a market cap of $58.99 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.87 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,170.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The business's fifty day moving average price is $563.69 and its 200 day moving average price is $581.96.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.56 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.